Publication in Journal of Medicinal Chemistry Highlights Molecular Insight Pharmaceuticals’ Program for Targeting Prostate Cancer
12/30/2008 8:32:50 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today the publication of a preclinical study describing the synthesis and initial evaluation of two series of radiolabeled small molecules that target prostate-specific membrane antigen (PSMA), a validated molecular marker for prostate cancer. The lead compounds, MIP-1072 and MIP-1095, demonstrated high affinity and specific binding to PSMA on human prostate cancer cells, and the radiolabeled analogs provide the foundation for the Company’s Trofex prostate cancer molecular imaging program, which is currently undergoing an exploratory Phase 1 clinical trial in patients with histological confirmed prostate cancer and evidence of recurrent disease. The goal of the clinical trial is to select the more promising of the two compounds for further clinical development and commercialization.